Multiple Sclerosis - FTY720 (Fingolimod) Trial Results

Main Category: Multiple Sclerosis
Also Included In: Clinical Trials / Drug Trials
Article Date: 15 Dec 2008 - 0:00 PDT

email to a friend   printer friendly   opinions  

FTY720 (fingolimod), an experimental oral drug for relapsing MS is more effective than current treatments according to new research reported today.

The trial, called TRANSFORMS, is the first of three studies of FTY720 to report. TRANSFORMS was a one year study involving 1,292 participants receiving either 0.5 mg or 1.25 mg FTY720 or interferon beta-1a (Avonex).

During the study, people receiving interferon beta-1a experienced on average 0.33 relapses. People on the lower dose of FTY720 experienced 0.16 relapses (a reduction of 52%) and those on the higher dose 0.20 relapses (a 38% reduction).

The study data is still being analysed and detailed results are planned to be presented at a conference in 2009. The manufacturers, Novartis, hope to submit the drug for licensing by the end of 2009.

Pam Macfarlane, Chief Executive of the MS Trust said, "We welcome the positive results of the study. However, these are early results from a study looking at a short period of treatment. We look forward to the fuller results which we hope will give a clearer picture of the effectiveness of this drug for people with MS."

Source
Simon Webster
http://www.mstrust.org.uk

• Additional
• References
• Citations